Ausper Biopharma initiates AHB-171 trial for chronic hepatitis B
Ausper Biopharma is conducting an open-label trial to assess the efficacy and safety of AHB-171 in chronic hepatitis B patients.
Asset / Drug
Drug and asset intelligence for AHB-171 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.